Efficacy and outcome of molecular targeted therapies in elderly patients with hepatocellular carcinoma: Relative dose intensity associated with overall survival

Author:

Oura Kyoko1ORCID,Morishita Asahiro1ORCID,Takuma Kei1,Nakahara Mai1,Tadokoro Tomoko1ORCID,Fujita Koji1ORCID,Mimura Shima1,Tani Joji1ORCID,Ono Masafumi1,Himoto Takashi2,Masaki Tsutomu1

Affiliation:

1. Department of Gastroenterology and Neurology, Faculty of Medicine Kagawa University Kagawa Japan

2. Department of Medical Technology Kagawa Prefectural University of Health Sciences Kagawa Japan

Abstract

AbstractAimIndications of drug therapies to elderly patients with hepatocellular carcinoma (HCC) should be carefully determined. The current study assessed the safety and efficacy of molecular targeted agents (MTAs) in the elderly patients with HCC, and identified factors associated with prognosis in a real‐world clinical setting.MethodsIn a retrospective observational study, clinical data of patients with unresectable HCC treated with sorafenib or lenvatinib as first‐line treatment at our hospital between 2011 and 2022, were investigated. Clinical parameters, therapeutic effects, adverse events (AEs), and prognosis were evaluated separately for the non‐elderly (<75 years old) and elderly patients (≥75 years old).ResultsOverall, 111 patients were enrolled, including 59 non‐elderly and 52 elderly patients. Compared to the non‐elderly patients, the elderly patients had significantly lower skeletal muscle mass and a significantly lower percentage of patients in poor general condition with performance status 2 or higher, but there were no differences in parameters related to liver function or nutritional status. There were no significant differences in the incidence of severe AEs and therapeutic effects between the groups. No significant difference in progression‐free survival was observed in the elderly and non‐elderly patients; however, overall survival (OS) for sorafenib treatment was shorter in the elderly patients than in the non‐elderly patients. Elderly patients consumed lower doses of both the drugs, and relative dose intensity (RDI) 4 weeks after treatment (4W‐RDI) was associated with OS. Further, OS in the elderly patients was significantly longer in the subgroup with high 4W‐RDI as compared to that in the subgroup with low 4W‐RDI.ConclusionsMTAs can be safely administered to elderly patients with HCC. Furthermore, 4W‐RDI is associated with longer OS. Maintaining RDI in the early phase is crucial in predicting the success of treatment with MTAs, especially in the elderly patients.

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3